Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/73859
Título
The IRE1α-XBP1 arm of the unfolded protein response is a host factor activated in SARS-CoV-2 infection
Autor
Año del Documento
2024
Editorial
Elsevier
Descripción
Producción Científica
Documento Fuente
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1870, Issue 5, June 2024, 167193
Resumen
SARS-CoV-2 infection can cause severe pneumonia, wherein exacerbated inflammation plays a major role. This is reminiscent of the process commonly termed cytokine storm, a condition dependent on a disproportionated production of cytokines. This state involves the activation of the innate immune response by viral patterns and coincides with the biosynthesis of the biomass required for viral replication, which may overwhelm the capacity of the endoplasmic reticulum and drive the unfolded protein response (UPR). The UPR is a signal transduction pathway composed of three branches that is initiated by a set of sensors: inositol-requiring protein 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6). These sensors control adaptive processes, including the transcriptional regulation of proinflammatory cytokines. Based on this background, the role of the UPR in SARS-CoV-2 replication and the ensuing inflammatory response was investigated using in vivo and in vitro models of infection. Mice and Syrian hamsters infected with SARS-CoV-2 showed a sole activation of the Ire1α-Xbp1 arm of the UPR associated with a robust production of proinflammatory cytokines. Human lung epithelial cells showed the dependence of viral replication on the expression of UPR-target proteins branching on the IRE1α-XBP1 arm and to a lower extent on the PERK route. Likewise, activation of the IRE1α-XBP1 branch by Spike (S) proteins from different variants of concern was a uniform finding. These results show that the IRE1α-XBP1 system enhances viral replication and cytokine expression and may represent a potential therapeutic target in SARS-CoV-2 severe pneumonia.
Materias (normalizadas)
Biomedicina
Materias Unesco
24 Ciencias de la Vida
Palabras Clave
COVID-19 Cytokines Fluvoxamine Pneumonia TLR Transcription factors Unfolded protein response Viral sepsis Variants of concern
Revisión por pares
SI
Patrocinador
Junta de Castilla y León/Fondo Social Europeo Grants CSI035P17 and VA175P20
Plan Nacional de Salud y Farmacia Grant SAF2017-83079-R and Grant PID2020-113751RB-I00 funded by MCIN/AEI/ 10.13039/501100011033
European Commission-NextGenerationEU, (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global)
Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA)
Fondo COVID-19 del Instituto de Salud Carlos III/Junta de Castilla y León
U.S. Food and Drug Administration Medical Countermeasures Initiative contract (75F40120C00085)
G2P-UK: A national virology consortium to address phenotypic consequences of SARS-CoV-2 genomic variation
National Institutes of Health (NIH) grant: R21AI147172 (N.I.), NIH/NIAID R01AI160706, NIH/NIAID R21AI176069, and NIH/NIDDK R01DK130425
This work was also partly supported by NIAID grant U19AI135972, and by CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIAID funded Center of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014) (A.G.S.). This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.
Plan Nacional de Salud y Farmacia Grant SAF2017-83079-R and Grant PID2020-113751RB-I00 funded by MCIN/AEI/ 10.13039/501100011033
European Commission-NextGenerationEU, (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global)
Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA)
Fondo COVID-19 del Instituto de Salud Carlos III/Junta de Castilla y León
U.S. Food and Drug Administration Medical Countermeasures Initiative contract (75F40120C00085)
G2P-UK: A national virology consortium to address phenotypic consequences of SARS-CoV-2 genomic variation
National Institutes of Health (NIH) grant: R21AI147172 (N.I.), NIH/NIAID R01AI160706, NIH/NIAID R21AI176069, and NIH/NIDDK R01DK130425
This work was also partly supported by NIAID grant U19AI135972, and by CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIAID funded Center of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014) (A.G.S.). This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.
Version del Editor
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Aparece en las colecciones
Ficheros en el ítem
Tamaño:
725.9Kb
Formato:
Adobe PDF
Descripción:
Artículo de investigación
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional